EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Atractylodin Ameliorates Colitis via PPARα Agonism

Gwangbeom Heo, Yuju Kim, Eun-La Kim, Soyeong Park, Sang Hoon Rhee iD, Jee H Jung, Eunok Im iD

International Journal of Molecular Sciences · 02.01.2023 · 24 (1) · 802

DOI: 10.3390/ijms24010802 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 02.01.2023. Verfasst von Gwangbeom Heo und 6 weiteren Autor:innen. Beteiligte Einrichtung: College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea. Hauptthemen laut MEDLINE: PPAR alpha, Colitis. Die Arbeit wurde bisher 27-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, Financial Supporting Project of Long-term Overseas Dispatch of PNU’s Tenure-track Faculty.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Atractylodin is a major compound in the rhizome of Atractylodes lancea, an oriental herbal medicine used for the treatment of gastrointestinal diseases, including dyspepsia, nausea, and diarrhea. Recent studies have shown that atractylodin exerts anti-inflammatory effects in various inflammatory diseases. Herein, we investigated the anti-colitis effects of atractylodin and its molecular targets. We determined the non-cytotoxic concentration of atractylodin (50 μM) using a cell proliferation assay in colonic epithelial cells. We found that pretreatment with atractylodin significantly inhibits tumor necrosis factor-α-induced phosphorylation of nuclear factor-κ-light-chain-enhancer of activated B in HCT116 cells. Through docking simulation analysis, luciferase assays, and in vitro binding assays, we found that atractylodin has an affinity for peroxisome proliferator-activated receptor alpha (PPARα). Daily administration of atractylodin (40 mg/kg) increased the survival rate of mice in a dextran sodium sulfate-induced colitis mouse model. Thus, atractylodin can be a good strategy for colitis therapy through inducing PPARα-dependent pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PPAR alphaColitisAnimalsMicePhosphorylationFuransMice, Inbred C57BLDextran Sulfate

Stichwörter der Autor:innen

Atractylodes lanceaPPAR alphaatractylodininflammatory bowel disease

Substanzen

atractylodinPPAR alphaFuransDextran Sulfate

Autor:innen und Institutionen

  • College of Pharmacy, Pusan National University, Busan 46241, Republic of Korea.
  • Department of Biological Sciences, Oakland University, Rochester, MI 48309, USA.
  • Research Institute for Drug Development, Pusan National University, Busan 46241, Republic of Korea.

ORCID-Profile: Sang Hoon Rhee, Eunok Im

Förderung

  • NIDDK NIH HHS
  • Financial Supporting Project of Long-term Overseas Dispatch of PNU’s Tenure-track Faculty

Zitieren

APA

Heo, G., Kim, Y., Kim, E. L., Park, S., Rhee, S. H., Jung, J. H., & Im, E. (2023). Atractylodin Ameliorates Colitis via PPARα Agonism. International Journal of Molecular Sciences, 24(1), 802. https://doi.org/10.3390/ijms24010802

Vancouver

Heo G, Kim Y, Kim EL, Park S, Rhee SH, Jung JH, et al. Atractylodin Ameliorates Colitis via PPARα Agonism. International Journal of Molecular Sciences. 2023;24(1):802. doi:10.3390/ijms24010802

BibTeX
@article{Heo2023,
  author = {Heo, Gwangbeom and Kim, Yuju and Kim, Eun-La and Park, Soyeong and Rhee, Sang Hoon and Jung, Jee H and Im, Eunok},
  title = {Atractylodin Ameliorates Colitis via PPARα Agonism},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {1},
  pages = {802},
  doi = {10.3390/ijms24010802}
}
Kostenlos starten →